Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Harpoon Therapeutics

Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma
From Harpoon Therapeutics
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Harpoon Therapeutics
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023
From Harpoon Therapeutics
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023
From Harpoon Therapeutics
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics to Participate in the Canaccord Horizons in Oncology Conference
From Harpoon Therapeutics
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Harpoon Therapeutics
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics Announces Closing of $25 Million Private Placement
From Harpoon Therapeutics
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023
From Harpoon Therapeutics
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics to Participate in the SVB Securities Global Biopharma Conference
From Harpoon Therapeutics
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
From Harpoon Therapeutics
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022
From Harpoon Therapeutics
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
From Harpoon Therapeutics
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial Results
From Harpoon Therapeutics
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition
From Harpoon Therapeutics
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer
From Harpoon Therapeutics
Via GlobeNewswire
Tickers HARP
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.